Mirvetuximab soravtansine (IMGN853), as an ADC, involves a humanized anti-FRα monoclonal antibody targeting selective tumor cells and tubulin-disrupting maytansinoid DM4 as a cytotoxic module [195, 198]. This evidence concerns the gene FOLR1 and neoplasm.